Fusion Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview

Fusion Pharmaceuticals

03/11/2023 16:50

* Fusion Pharmaceuticals Inc  FUSN.OQ   FUSN.O  is expected
to show a fall in quarterly revenue when it reports  results 
    * The Hamilton Ontario Ontario-based  company is expected to
report  a 42.4% decrease in revenue to $95.56 thousand from $166
thousand a year ago, according to the mean estimate from 9
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Fusion
Pharmaceuticals
Inc is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $12​, above​ its last closing price
of $4.55. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.38       -0.39      -0.38     Beat    2.3
 Mar. 31 2023  -0.32       -0.32      -0.45     Missed  -41.7
 Dec. 31 2022  -0.56       -0.56      -0.55     Beat    1.1​
 Sep. 30 2022  -0.51       -0.50      -0.55     Missed  -10
 ​​Jun.        -0.53       -0.53      -0.44     Beat    17.4
 30 2022                                                
 Mar. 31 2022  -0.47       -0.48      -0.46     Beat    4.2​
 Dec. 31 2021  -0.42       -0.47      -0.40     Beat    14.3
 Sep. 30 2021  -0.61       -0.60      -0.45     Beat    24.7
 This summary was machine generated November 3 at 16:50 GMT.  All
figures in US dollars  unless otherwise stated